Genetesis, Inc. is a medical technology company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with proprietary cloud-based web services and machine-learning capabilities, we seek to become the standard of care for diagnosis of clinically significant myocardial ischemia in the acute care setting. We continue to partner with forward-thinking clinicians to rigorously validate our technology and develop new areas of application. Genetesis was founded in 2013 and is based in Mason, Ohio.
Learn more at https://www.genetesis.com !